Medication info
Dayabsmet Tablet 50/1000 mg (Vildagliptin, Metformin Hydrochloride)

Dayabsmet Tablet 50/1000 mg (Vildagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Vildagliptin›50mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Korea Hutech Pharmaceutical Co., Ltd.
Appearance
Dark yellow oval film-coated tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 202302281 · Approved 2023.07.28 · Insurance code 649105790

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding vildagliptin 100mg and metformin 2000mg. Doses of vildagliptin of 100mg or more per day are not recommended. This medicine should generally be taken with food or immediately after a meal to reduce gastrointestinal adverse reactions caused by metformin. Patients with no prior experience of antidiabetic drug therapy in whom adequate glycemic control is not achieved with monotherapy: The initial dose of this medicine is 1 tablet of 50/500mg once daily. The dose may be gradually increased to 1 tablet of 50/1000mg 2 times daily. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should provide vildagliptin 100mg per day and the patient's existing dose of metformin. The initial dose of this medicine should be determined according to the patient's current treatment regimen; take 1 tablet of this medicine 50mg/850mg or 50mg/1000mg in the morning and evening, 2 times daily. Patients switching from concomitant therapy with vildagliptin and metformin: Patients switching from concomitant therapy with vildagliptin and metformin to this medicine may start at their existing doses of vildagliptin and metformin. When used in combination with a sulfonylurea or insulin: Administer vildagliptin 50mg 2 times daily (total daily dose 100mg) and administer metformin at a dose similar to the existing dose. When this medicine is used in combination with a sulfonylurea, the sulfonylurea dose may need to be reduced to lower the risk of hypoglycemia. If you miss a dose of this medicine, take it with your next meal unless it is time to take the missed dose. Do not take a double dose at one time to make up for a missed dose. This medicine is not recommended for patients with hepatic impairment.

Ingredients

Manufacturer
Korea Hutech Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication is used to assist in blood sugar control in patients with type 2 diabetes taking vildagliptin and metformin together and is intended to complement dietary and exercise management. It is effective for those whose blood sugar is not well controlled and can help manage blood sugar levels when taken consistently. Therefore, this medication is indicated for blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding vildagliptin 100mg and metformin 2000mg. Doses of vildagliptin of 100mg or more per day are not recommended. This medicine should generally be taken with food or immediately after a meal to reduce gastrointestinal adverse reactions caused by metformin. Patients with no prior experience of antidiabetic drug therapy in whom adequate glycemic control is not achieved with monotherapy: The initial dose of this medicine is 1 tablet of 50/500mg once daily. The dose may be gradually increased to 1 tablet of 50/1000mg 2 times daily. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should provide vildagliptin 100mg per day and the patient's existing dose of metformin. The initial dose of this medicine should be determined according to the patient's current treatment regimen; take 1 tablet of this medicine 50mg/850mg or 50mg/1000mg in the morning and evening, 2 times daily. Patients switching from concomitant therapy with vildagliptin and metformin: Patients switching from concomitant therapy with vildagliptin and metformin to this medicine may start at their existing doses of vildagliptin and metformin. When used in combination with a sulfonylurea or insulin: Administer vildagliptin 50mg 2 times daily (total daily dose 100mg) and administer metformin at a dose similar to the existing dose. When this medicine is used in combination with a sulfonylurea, the sulfonylurea dose may need to be reduced to lower the risk of hypoglycemia. If you miss a dose of this medicine, take it with your next meal unless it is time to take the missed dose. Do not take a double dose at one time to make up for a missed dose. This medicine is not recommended for patients with hepatic impairment.

Precautions

This medication may cause severe lactic acidosis or hypoglycemia, so caution is required. Especially, it should not be used in patients with moderate to severe renal impairment or heart failure, and in patients with severe conditions such as acute myocardial infarction or sepsis. If a patient is undergoing tests using iodine contrast media, this medication should be stopped 48 hours prior to the test and reinitiated only after renal function has been confirmed to be normal. It is safest for pregnant or breastfeeding women to avoid this medication. Caution is needed in cases of irregular meals or insufficient food intake, vigorous exercise, or concurrent use of other medications due to the risk of lactic acidosis and hypoglycemia. Patients may experience headaches, dizziness, nausea, and symptoms of hypoglycemia during treatment, so they should consult a doctor if any unusual symptoms occur. Patients with liver impairment should regularly undergo liver function tests due to the risk of worsening liver function and lactic acidosis, and they should stop taking the medication if any abnormal findings are detected. In cases of reduced kidney function, there is an increased risk of drug accumulation and lactic acidosis, so kidney function should be monitored periodically, and the medication should be discontinued if kidney function worsens. Alcohol may increase the risk of lactic acidosis with this medication, so excessive drinking should be avoided during treatment. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, and it does not replace the need for insulin therapy if it is required. Patients scheduled for surgery should stop taking this medication 48 hours prior to surgery and resume once oral ingestion has normalized and kidney function has recovered. Elderly patients are commonly at risk for decreased kidney function, so dosing adjustments and regular kidney function monitoring are necessary. In cases of overdose, supportive care is required, and the metformin component can be removed through dialysis, so appropriate treatment is needed in emergencies. If any abnormalities such as blisters or ulcers appear on the skin during treatment, consult a doctor immediately. If blood sugar control is insufficient or if symptoms of hypoglycemia occur, it is necessary to discuss dosage adjustments or treatment plans with healthcare professionals. During treatment with this medication, it is important to regularly monitor blood sugar levels, blood tests, especially vitamin B12 levels.

Side effects

  • Severe lactic acidosis
  • hypoglycemia
  • hepatitis
  • liver dysfunction
  • elevated transaminase levels
  • angioedema
  • tremors
  • headache
  • dizziness
  • fatigue
Show 36 more
  • nausea
  • hypoglycemia
  • gastroesophageal reflux
  • diarrhea
  • bloating
  • chills
  • reduced blood sugar
  • asthenia
  • hyperhidrosis
  • constipation
  • arthralgia
  • upper respiratory infection
  • nasopharyngitis
  • peripheral edema
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • taste disorder
  • erythema
  • pruritus
  • urticaria
  • pancreatitis
  • urticaria
  • blisters
  • exfoliative skin lesions
  • severe and debilitating arthralgia
  • cutaneous vasculitis
  • cholecystitis
  • dyspepsia
  • abdominal discomfort
  • gastrointestinal disturbances
  • increased serum amylase
  • increased lipase
  • vesicular pemphigoid

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so the bottle must be tightly closed and stored in a sealed state. Additionally, it is recommended to store it in a cool place below 30 degrees Celsius to avoid excessive heat.

Appearance and packaging

Appearance

Dark yellow oval film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.